Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646566 · ClinicalTrials.gov registry record · Phase 3
Study of APD421 as PONV Treatment (Prior Prophylaxis)
A Phase 3 study of Postoperative Nausea and Vomiting, sponsored by Acacia Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 8
- Study locations
NCT02646566 is a Phase 3 study of Postoperative Nausea and Vomiting that has completed, run by Acacia Pharma. The registered enrollment target is 705 participants, above the 393-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (79% higher). The trial reports 8 study locations across 4 states.
The verdict
NCT02646566, a Phase 3 study of Postoperative Nausea and Vomiting, has completed, sponsored by Acacia Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 8
- Study locations
Study Summary
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG APD421
Study Locations (8)
Other
- CHU de Hautepierre - Strasbourg
- HELIOS Klinikum Aue - Aue
- Universität Heidelberg - Heidelberg
- Philipps University - Marburg
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University School of Medicine - Winston-Salem
Florida
- Jackson Memorial Hospital - Miami
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02646566
The ClinicalTrials.gov registry entry for NCT02646566 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 393-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (79% higher). The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02646566 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT02646566 about?
NCT02646566 is a clinical study titled "Study of APD421 as PONV Treatment (Prior Prophylaxis)". Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
What is the current status of trial NCT02646566?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2016-03. Estimated completion is 2017-01.
What conditions does trial NCT02646566 study?
This clinical trial studies the following conditions: Postoperative Nausea and Vomiting.
What interventions are being tested in trial NCT02646566?
The interventions under investigation include: Placebo (DRUG), APD421 (DRUG).
Who is sponsoring clinical trial NCT02646566?
This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646566 being conducted?
This trial has 8 study locations across Florida, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea and Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
COMPLETED · Phase 3
-
Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.
RECRUITING · NA
-
Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery
RECRUITING · Phase 2
-
Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients
COMPLETED
-
Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children
COMPLETED
-
Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.